3D printing represents a new era in the field of digital manufacturing, finding its applications in
many industries, such as healthcare, automotive, and aerospace. In particular, 3D printing has the
potential to completely revolutionize the manufacturing process for implants, medical
equipment, and even human tissues within the healthcare industry. The rapid rise of 3D printing
raises fundamental questions i.e., Is this technology truly revolutionary, or does it perhaps take
us in a direction other than we might expect? This editorial aim to consider the dual-edged nature
of 3D printing, with particular respect to biomaterials, and argue for a more selective and
responsible approach in using it. Furthermore, the importance of regulatory frameworks in
ensuring the safety and effectiveness of 3D printing for healthcare applications cannot be
overlooked. While such frameworks are well-established in the EU, UK, and USA, they are
notably absent in the MENA region.